Please read these conditions carefully before using this site. By using this site, you signify your assent to the following terms and conditions of use without limitation or qualification. In particular, you consent to the use of all cookies on this website for the purposes described in the terms of use. If you do not agree to these terms or to the use of cookies as described below, do not use this site. AllianceBernstein may at any time revise these terms of use. You are bound by any such revisions and should therefore periodically visit this page to review the then current terms of use to which you are bound. This site is for informational purposes and does not constitute an offer to sell or a solicitation of an offer to buy any security which may be referenced herein.
This site is solely intended for use by professional/institutional investors and institutional-investment industry consultants.
Do you wish to continue?
13 Years at AB|25 Years of Experience
Vinay Thapar is a Senior Vice President and Co-Chief Investment Officer for US Growth Equities and a Portfolio Manager for the Global Healthcare Strategy. He is also a Senior Research Analyst, responsible for covering global healthcare. Before joining the firm in 2011, Thapar spent three years at American Century Investments as a senior investment analyst responsible for healthcare. Prior to that, he worked for eight years at Bear Stearns in the Biotech Equity Research Group, most recently as an associate director. Thapar holds a BA in biology from New York University and is a CFA charterholder. Location: New York
Healthcare stocks are in much better shape than equity investors might think.
Vinay Thapar | February 24, 2025Healthcare companies often grab headlines for their exciting drug innovations. But we think the focus should be on business fundamentals.
Vinay Thapar | November 12, 2024Drugmakers don't have to dominate a healthcare portfolio. Equity investors should cast a wide net across the sector to find innovation and growth.
Vinay Thapar | October 29, 2024Questions are being asked about the US managed care industry, but some businesses are equipped to rise to the challenge.
Ewa Przybylko, Vinay Thapar | May 15, 2024Despite conventional wisdom, political uncertainty doesn’t necessarily pose acute risks to the healthcare sector.
Vinay Thapar, Edward Bryan | February 27, 2024Even the best scientists in the world cannot reliably forecast drug-test results, so why should investors gamble? Quality businesses are key for healthcare stocks.
Vinay Thapar | September 21, 2023To transform science fiction into reality, AI applications in the healthcare sector must prove that they can improve business profitability to deliver returns for investors.
Vinay Thapar | June 08, 2023Stocks have advanced this year, though markets have been volatile and investors are grappling with tough challenges. We asked three of our equity portfolio managers to share their thoughts on investing in the current environment.
Kent Hargis, Ben Ruegsegger, Vinay Thapar | June 05, 2023Everyone's trying to figure out what happens with the economy and what will be the impact of interest rates. But what you really want to do at the end of the day is buy good businesses
Vinay Thapar | March 29, 2023Technology and healthcare are good examples of sectors that can play different equity-allocation roles than you might expect.
Kent Hargis, Vinay Thapar | March 21, 2023Demand for healthcare products tends to stay resilient during periods of inflation. That’s good news for equity investors in the sector.
Vinay Thapar | March 01, 2023Investors in US growth stocks can find a broader array of recovery candidates with resilient businesses and solid profitability.
Vinay Thapar, John Fogarty | February 27, 2023The sources of the healthcare sector's appeal can provide resilient equity return potential through uncertain market conditions in 2023.
Vinay Thapar | January 11, 2023Technology and creative research should continue to drive company breakthroughs in medicine and packaging.
Edward Bryan, Vinay Thapar | November 01, 2022Investing in healthcare stocks is still a defensive strategy, but the sector's scope of companies—and how investors should think about them—have evolved.
Vinay Thapar | July 25, 2022Growth stocks are under acute pressure. But companies that can deliver sustainable growth in a sluggish economy will ultimately be prized for their potential.
Vinay Thapar, John Fogarty | May 31, 2022Investors who look for strong business characteristics can find exciting opportunities-across the healthcare continuum and around the world.
Vinay Thapar | January 24, 2022In today's rapidly changing market conditions, identifying companies with the right characteristics is a strategic necessity.
Vinay Thapar, John Fogarty | January 20, 2022Capital efficient companies that are reinvesting profits back into the business have clear advantages in today's unpredictable markets.
Vinay Thapar | November 11, 2021Returns for healthcare stocks have been disappointing through the market's recovery from the pandemic. But there's still plenty of promising growth potential to be found. These four questions can help investors identify areas of interest.
Ryan Oden, Vinay Thapar | June 08, 2021Hunting for a COVID-19 vaccine isn't a great strategy for healthcare investors. Focusing on business fundamentals is a much better way to find stocks with long-term potential than searching for any potential blockbuster drug.
Vinay Thapar | November 24, 2020Healthcare stocks usually are defensive for a portfolio during market downturns. Given the extent of the pandemic's impact, more questions are being asked about the sector's resilience.
Vinay Thapar | May 07, 2020US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to political noise.
Vinay Thapar | February 06, 2020While many investors in healthcare stocks may try to focus on predicting scientific outcomes, we take a different approach. We look at the return on invested capital (ROIC), and that's how we find opportunities.
Vinay Thapar | September 11, 2018